TECENTRIQ (atezolizumab) and TECENTRIQ HYBREZA (atezolizumab and hyaluronidase-tqjs) plus chemotherapy
Adjuvant treatment of stage III dMMR/MSI-H colon cancer · Patients with resected stage III deficient DNA mismatch repair or microsatellite instability-high colon cancer
RHHBY · Roche Holdings AG
Regulatory designations
Full timeline
4 milestonesFDA approved Tecentriq and Tecentriq Hybreza
FDA approved the atezolizumab regimens with fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III dMMR colon cancer, one day before the PDUFA goal date.
FDA — Tecentriq approval notice↗FDA decision expected
FDA assigned an October 9, 2026 PDUFA goal date to the supplemental BLA for TECENTRIQ and TECENTRIQ HYBREZA in combination with chemotherapy for adjuvant treatment of stage III dMMR/MSI-H colon cancer.
Roche — Tecentriq sBLA acceptance and PDUFA date↗FDA accepted the sBLA with Priority Review
FDA accepted the supplemental BLA and granted Priority Review based on the Phase 3 Alliance ATOMIC study.
Roche — Tecentriq sBLA acceptance and Priority Review↗Phase 3 ATOMIC data supported the filing
The Phase 3 ATOMIC study found that adding TECENTRIQ to FOLFOX6 chemotherapy reduced the risk of recurrence or death by 50% versus chemotherapy alone in stage III dMMR colon cancer.
Roche — ATOMIC efficacy results↗Related News
FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer
Nov 16, 2026Roche’s Gazyva/Gazyvaro becomes the first FDA-approved treatment for primary membranous nephropathy
Nov 13, 2026CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for systemic lupus erythematosus (SLE)
Nov 10, 2026Roche presents new data across pharmaceuticals and diagnostics from its growing Alzheimer’s disease portfolio at CTAD 2026
Oct 28, 2026Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma
